Trial Profile
A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Aug 2020 Status changed from recruiting to completed.
- 02 Jun 2015 Results of sub-group analysis presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.